These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28679468)

  • 1. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
.
    Min KC; Lasseter KC; Marbury TC; Wrishko RE; Hanley WD; Wolford DG; Udo de Haes J; Reitmann C; Gutstein DE
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):746-752. PubMed ID: 28679468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment.
    Panhuizen IF; Gold SJ; Buerkle C; Snoeck MM; Harper NJ; Kaspers MJ; van den Heuvel MW; Hollmann MW
    Br J Anaesth; 2015 May; 114(5):777-84. PubMed ID: 25829395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial.
    de Souza CM; Tardelli MA; Tedesco H; Garcia NN; Caparros MP; Alvarez-Gomez JA; de Oliveira Junior IS
    Eur J Anaesthesiol; 2015 Oct; 32(10):681-6. PubMed ID: 26225497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.
    Staals LM; Snoeck MM; Driessen JJ; Flockton EA; Heeringa M; Hunter JM
    Br J Anaesth; 2008 Oct; 101(4):492-7. PubMed ID: 18653492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
    Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
    J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
    Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
    Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
    Cammu G; De Kam PJ; Demeyer I; Decoopman M; Peeters PA; Smeets JM; Foubert L
    Br J Anaesth; 2008 Mar; 100(3):373-9. PubMed ID: 18238834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
    Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
    Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.
    Staals LM; Snoeck MM; Driessen JJ; van Hamersvelt HW; Flockton EA; van den Heuvel MW; Hunter JM
    Br J Anaesth; 2010 Jan; 104(1):31-9. PubMed ID: 20007792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex is cleared rapidly and primarily unchanged via renal excretion.
    Peeters P; Passier P; Smeets J; Zwiers A; de Zwart M; van de Wetering-Krebbers S; van Iersel M; van Marle S; van den Dobbelsteen D
    Biopharm Drug Dispos; 2011 Apr; 32(3):159-67. PubMed ID: 21370235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex.
    Kam PJ; Heuvel MW; Grobara P; Zwiers A; Jadoul JL; Clerck Ed; Ramael S; Peeters PA
    Clin Drug Investig; 2012 Mar; 32(3):203-12. PubMed ID: 22201295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
    de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
    Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
    Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex.
    Ploeger BA; Smeets J; Strougo A; Drenth HJ; Ruigt G; Houwing N; Danhof M
    Anesthesiology; 2009 Jan; 110(1):95-105. PubMed ID: 19104176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.
    Peeters PA; van den Heuvel MW; van Heumen E; Passier PC; Smeets JM; van Iersel T; Zwiers A
    Clin Drug Investig; 2010; 30(12):867-74. PubMed ID: 20825252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: A randomized comparison of sugammadex reversal with spontaneous recovery.
    Rahe-Meyer N; Berger C; Wittmann M; Solomon C; Abels EA; Rietbergen H; Reuter DA
    Anaesthesist; 2015 Jul; 64(7):506-12. PubMed ID: 26126940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.
    Dale GE; Halabi A; Petersen-Sylla M; Wach A; Zwingelstein C
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.